Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review
Brendle M, Ragnhildstveit A, Slayton M, Smart L, Cunningham S, Zimmerman M, Seli P, Gaffrey M, Averill L, Robison R. Registered clinical trials investigating ketamine and esketamine for treatment-resistant depression: A systematic review. Journal Of Psychedelic Studies 2023, 6: 176-187. DOI: 10.1556/2054.2022.00234.Peer-Reviewed Original ResearchTreatment-resistant depressionMontgomery-Asberg Depression Rating ScaleDepression Rating ScaleLate-phase trialsTrial eligibilityPatient characteristicsDrug regimensClinical outcomesResults databaseRegistered trialsClinical trialsTreatment responseEsketaminePharmacological approachesPRISMA guidelinesCombination treatmentMost trialsClinical practiceElectronic registryKetamineSystematic reviewFinal reviewTherapeutic useQualitative synthesisStudy designThe potential of ketamine for posttraumatic stress disorder: a review of clinical evidence
Ragnhildstveit A, Roscoe J, Bass L, Averill C, Abdallah C, Averill L. The potential of ketamine for posttraumatic stress disorder: a review of clinical evidence. Therapeutic Advances In Psychopharmacology 2023, 13: 20451253231154125. PMID: 36895431, PMCID: PMC9989422, DOI: 10.1177/20451253231154125.Peer-Reviewed Original ResearchPosttraumatic stress disorderClinical evidenceStress disorderMethyl-d-aspartate (NMDA) receptor antagonistLow patient engagementRobust antidepressant effectsOpen-label studyOnset of actionPotential of ketamineQuality of lifeMedical comorbiditiesAntidepressant effectsChart reviewRefractory casesDisease chronicityClinical presentationRandomized trialsCase reportDevastating conditionReceptor antagonistMajor depressionPharmacological approachesPsychiatric disordersPharmacological agentsTherapeutic safety